Some Data, Please
By Genome Web,
Genome Web
| 01. 08. 2014
A company and its former subsidiary have settled with the US Federal Trade Commission, which said the companies' advertising claims regarding their genetically tailored nutritional supplements and skincare products were deceptive.
In their marketing material, GeneLink and Foru said that their customized products - customers sent in cheek swabs for genetic analysis - could help overcome genetic shortcomings, according to the FTC. For instance, included testimonials said that the supplements could treat diseases such as diabetes, heart disease, and insomnia, and that the effectiveness of the skin repair serum was scientifically proven. In addition, FTC says the companies did not have appropriate safeguards to ensure the privacy of customers' genetic information, Social Security numbers, and bank account information.
As part of the proposed settlement, the companies would be barred from making claims that their products prevent, treat, or reduce the risk of any disease unless it is true and backed up by at least two well-controlled studies. In addition, any claim saying that a product treats or prevents a disease in someone with certain genetic variation has to be...
Related Articles
By Emily Mullin, Wired | 10.30.2025
In 2018, Chinese scientist He Jiankui shocked the world when he revealed that he had created the first gene-edited babies. Using Crispr, he tweaked the genes of three human embryos in an attempt to make them immune to HIV and...
Public domain portrait of James D. Watson by Cold Spring Harbor Laboratory
and the National Human Genome Research Institute on Wikimedia Commons
James Watson, a scientist famous for ground-breaking work on DNA and notorious for expressing his antediluvian opinions, died on November 6, at the age of 97. Watson’s scientific eminence was primarily based on the 1953 discovery of the helical structure of DNA, for which he, Francis Crick and Maurice Wilkins shared the 1962 Nobel Prize in Physiology or...
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...
Paula Amato & Shoukhrat Mitalipov
[OHSU News/Christine Torres Hicks]
On September 30th, a team of 21 scientists from Oregon Health & Science University (OHSU) published a significant paper in Nature Communications, with a scientifically accurate but, to many, somewhat abstruse headline:
Induction of experimental cell division to generate cells with reduced chromosome ploidy
The lead authors were Shoukhrat Mitalipov, recently described here as “a push-the-envelope biologist,” and his long-term colleague Paula Amato. (Recall that in July the pair had co-published with...
